Brief: Kailera Therapeutics Says Phase 2 Ribupatide Oral Shows Up To 12.1% Mean Weight Loss At 26 Weeks
06/06/2026 24:40
BRIEF-Kailera Therapeutics Says Phase 2 Ribupatide Oral Shows Up To 12.1% Mean Weight Loss At 26 Weeks June 5 (Reuters) - Kailera Therapeutics Inc KLRA.O:
KAILERA THERAPEUTICS - PHASE 2 RIBUPATIDE ORAL SHOWS UP TO 12.1% MEAN WEIGHT LOSS AT 26 WEEKS
KAILERA THERAPEUTICS - RIBUPATIDE INJECTION SINGLE DOSE SHOWS UP TO 5.5% MEAN WEIGHT LOSS AT DAY 29
Source text: ID:nGNX2QQG3y
Further company coverage: KLRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kailera Therapeutics
See all newsKardigan surges in Nasdaq debut after upsized $400 million IPO (updated)
Brief: Kailera Therapeutics Says Phase 2 Ribupatide Oral Shows Up To 12.1% Mean Weight Loss At 26 Weeks
Advisory: Research alert on Kailera Therapeutics withdrawn
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut (updated)
Biotech firm Odyssey valued at $899.9 million as shares rises in Nasdaq debut